Functional apoptosis profiling reveals vulnerabilities in T-cell large granular lymphocytic leukemia
Evgenii Shumilov1,2, Paolo Mazzeo3, Marcel Trautmann4
1Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Münster (UKM), Münster, Germany.
Annals of Hematology
|February 6, 2025
Summary
Functional apoptosis profiling identified MCL-1 dependence in T-cell large granular lymphocytic leukemia (T-LGLL). This finding suggests AZD-5991 as a potential targeted therapy for patients with T-LGLL.
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- T-cell large granular lymphocytic leukemia (T-LGLL) is a rare cancer of cytotoxic T lymphocytes with variable clinical outcomes.
- Current treatments, mainly immunosuppression, are not always effective, and refractory disease is a challenge.
- Personalized therapeutic strategies are needed for T-LGLL.
Purpose of the Study:
- To investigate functional dependencies in T-LGLL for developing personalized therapies.
- To identify targetable anti-apoptotic mechanisms in T-LGLL cells.
Main Methods:
- Functional apoptosis profiling (BH3 profiling) was performed on malignant CD8+ T-cells and normal CD4+ T-cells from 8 T-LGLL patients.
- Ex vivo drug treatment with AZD-5991 was conducted on patient-derived T-LGLL cells.
- Genetic analysis, including STAT3 mutation status, was performed.
Main Results:
- The study highlighted the clinical and genetic heterogeneity of T-LGLL.
- Functional BH3 profiling revealed that 50% of patients (4/8) had T-LGLL cells with a dominant dependence on MCL-1.
- T-LGLL cells with enhanced MCL-1 dependence showed significant sensitivity to AZD-5991 ex vivo.
Conclusions:
- Functional apoptosis profiling can identify specific dependencies in T-LGLL.
- MCL-1 dependence is a targetable vulnerability in a subset of T-LGLL patients.
- AZD-5991 demonstrates potential as a targeted therapy for T-LGLL patients with MCL-1 dependence.
